ViaBio joins hands with Platinum Pharmaceuticals to incubate innovative pharmaceutical companies.

Guide: The two sides will integrate their respective resource advantages in the field of drug research and development, and jointly participate in incubating innovative biopharmaceutical enterprises.
Via Bio recently announced a strategic partnership with Heppey Pharmaceuticals, which will integrate their resource advantages in the field of drug research and development and jointly participate in incubating innovative biopharmaceutical companies.
this cooperation fully combines via biostructure-based early drug discovery services and platinum medicine with global patents and leading H2L2 all-human antibody genetically modified mouse platform and international innovative biological drug development experience, the two sides will use EFS (service-for-equity) and scientific research incubation model from the technical level to form effective complementarities, achieve synergies, jointly participate in the incubation of innovative biological drug enterprises, accelerate the process of new drug research and development.
via Bio provides the world's leading structured drug discovery service for innovative preclinical drug development for global biotech and pharmaceutical customers, covering a full range of customer needs for early drug discovery, including expression and structural research of target proteins, drug screening, pilot compound optimization until clinical candidates are identified.
Group's EFS (Service for Equity) business also provides drug discovery and incubation services to high-potential biotech start-ups around the world. Since its inception in late 2016,
and Platinum Pharmaceuticals have developed a number of strategic partnerships with the world's leading academic institutions, biotechnology and pharmaceutical companies.
through a diversified model of independent innovation and research and development and strategic project introduction, the company has successfully established a strong product pipeline, including a number of projects in the field of oncology immunology and immunology in the early and late development stages, to fill the unmet medical needs worldwide.
company makes full use of its own HCAb research and development platform, the next generation of CTLA-4 antibody HBM4003 for patients with solid tumors as a key project has entered the clinical phase of the trial phase. In response to this collaboration,
, ViaBio President Dr. Ren Delin said: "ViaBio's strategic partnership with Platinum Pharmaceuticals has filled the gap in viabio's platform for all-human-derived antibody genetically modified mice, and will further expand the scalability of Viabio's business model and enhance viabios' ability to attract and incubate more innovative potential enterprises."
" is pleased to partner with ViaBio, and by integrating our resources, we can provide innovative start-ups with the opportunity to have a next-generation technology platform and unique research and development capabilities.
and Platinum Pharmaceuticals have long been committed to providing innovative treatment options to improve human life, and this partnership can accelerate the provision of internationally influential products to patients. "We look forward to working with ViaBio to help highly innovative start-ups grow into industry leaders, providing diverse, comprehensive support," said Dr. Jinsong Wang, founder, chairman and chief executive officer of
" and Platinum Pharmaceuticals.
"